Brainstorm Cell Therapeutics (BCLI) Competitors $1.20 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.23 +0.03 (+2.08%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. NBRV, APLT, PLUR, PRLD, MURA, ATNM, SCLX, GRCE, XCUR, and ACRVShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), Exicure (XCUR), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Its Competitors Nabriva Therapeutics Applied Therapeutics Pluri Prelude Therapeutics Mural Oncology Actinium Pharmaceuticals Scilex Grace Therapeutics Exicure Acrivon Therapeutics Nabriva Therapeutics (NASDAQ:NBRV) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Is NBRV or BCLI more profitable? Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% Brainstorm Cell Therapeutics N/A N/A -519.50% Do insiders & institutionals have more ownership in NBRV or BCLI? 0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor NBRV or BCLI? In the previous week, Brainstorm Cell Therapeutics had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 0 mentions for Nabriva Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.84 beat Nabriva Therapeutics' score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nabriva Therapeutics Neutral Brainstorm Cell Therapeutics Positive Which has more risk & volatility, NBRV or BCLI? Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Which has stronger valuation and earnings, NBRV or BCLI? Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Nabriva Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/ABrainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.36-0.36 SummaryBrainstorm Cell Therapeutics beats Nabriva Therapeutics on 8 of the 12 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.81M$2.93B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.3620.5028.6119.73Price / SalesN/A267.14411.30174.40Price / CashN/A43.1536.0257.96Price / Book-0.887.768.235.67Net Income-$11.62M-$55.11M$3.23B$257.79M7 Day Performance-3.23%0.96%0.01%0.54%1 Month Performance-3.23%8.45%5.63%8.86%1 Year Performance-80.20%-2.37%26.55%14.22% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics1.2745 of 5 stars$1.20flatN/A-80.8%$11.81MN/A-0.3640News CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070APLTApplied Therapeutics4.538 of 5 stars$0.34+4.9%$6.10+1,717.6%-92.9%$45.30M$460K0.0030Positive NewsGap UpPLURPluri3.2919 of 5 stars$5.79+0.2%$12.00+107.3%-6.4%$45.28M$330K0.00150PRLDPrelude Therapeutics3.6873 of 5 stars$0.81+1.6%$4.50+457.8%-85.6%$44.82M$7M0.00120Positive NewsMURAMural Oncology3.1594 of 5 stars$2.48-3.9%$12.00+383.9%-24.8%$44.55MN/A0.00119ATNMActinium Pharmaceuticals2.8013 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230Positive NewsGap UpSCLXScilex2.546 of 5 stars$6.25-1.7%$455.00+7,180.0%-89.8%$44.21M$56.59M0.0080Positive NewsGRCEGrace Therapeutics2.5487 of 5 stars$3.00-4.2%$12.00+300.0%N/A$43.28MN/A0.00N/AGap DownXCURExicure1.3391 of 5 stars$6.47-4.6%N/A+1,999.3%$42.83M$500K0.0050Positive NewsGap DownACRVAcrivon Therapeutics3.7408 of 5 stars$1.25-3.1%$17.71+1,317.1%-82.9%$40.45MN/A0.0058Positive News Related Companies and Tools Related Companies NBRV Competitors APLT Competitors PLUR Competitors PRLD Competitors MURA Competitors ATNM Competitors SCLX Competitors GRCE Competitors XCUR Competitors ACRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
